| Literature DB >> 35655136 |
Sumaya Al Helali1, Muhammad Abid Hanif2, Ahmad Al Majed2, Nura Alshugair2, Abdullah Belfageih2, Hamad Al Qahtani2, Sameer Al Dulikan2.
Abstract
BACKGROUND: Blood lipids are strong risk factors for the progression of atherosclerotic plaques. However, data on gender-specific associations are limited.Entities:
Keywords: Angiography; Atherosclerosis; Computed tomography; Gender; Plaques; Saudi Arabia
Mesh:
Substances:
Year: 2022 PMID: 35655136 PMCID: PMC9164334 DOI: 10.1186/s12872-022-02690-x
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.174
Fig. 1A patient with clacified plaque (A). Coronary CT angiography showed proximal LAD calcified lesion in a patient with total coronary calcium score 86 HU. A patient with soft (non-calcified) plaque (B). Coronary CT angiography showed proximal LAD non-cacified lesion in a patient with total coronary calcium score zero
Adjusted* means and standard errors of blood lipids (mmol/L) by coronary plaque and gender groups
| No plaque | Soft plaque | Calcified plaque | Total | Pairwise difference | |||
|---|---|---|---|---|---|---|---|
| Total cholesterol | 4.66 ± 1.02 | 4.60 ± 1.03 | 4.56 ± 1.02 | 4.60 ± 1.01 | 0.457 | 0.005 | |
| LDL cholesterol | 2.81 ± 1.02 | 2.66 ± 1.04 | 2.70 ± 1.02 | 2.73 ± 1.02 | 0.169 | 0.730 | |
| HDL cholesterol | 1.10 ± 1.02 | 0.98 ± 1.03 | 1.03 ± 1.02 | 1.05 ± 1.01 | < 0.001 | < 0.001 | A, B |
| Triglycerides | 1.55 ± 1.03 | 1.76 ± 1.06 | 1.65 ± 1.04 | 1.60 ± 1.03 | 0.030 | < 0.001 | A |
| Total cholesterol | 4.62 ± 1.03 | 4.68 ± 1.04 | 4.81 ± 1.03 | 4.76 ± 1.01 | 0.185 | 0.005 | |
| LDL cholesterol | 2.65 ± 1.05 | 2.67 ± 1.07 | 2.70 ± 1.05 | 2.75 ± 1.02 | 0.859 | 0.730 | |
| HDL cholesterol | 1.25 ± 1.04 | 1.17 ± 1.05 | 1.28 ± 1.04 | 1.25 ± 1.02 | 0.128 | < 0.001 | |
| Triglycerides | 1.21 ± 1.07 | 1.31 ± 1.10 | 1.37 ± 1.07 | 1.39 ± 1.03 | 0.024 | < 0.001 | B |
| Total cholesterol | 4.66 ± 1.01 | 4.63 ± 1.02 | 4.64 ± 1.01 | 4.64 ± 1.01 | 0.921 | 0.072 | |
| LDL cholesterol | 2.76 ± 1.02 | 2.69 ± 1.03 | 2.72 ± 1.02 | 2.72 ± 1.02 | 0.476 | 0.367 | |
| HDL cholesterol | 1.15 ± 1.02 | 1.02 ± 1.03 | 1.07 ± 1.02 | 1.08 ± 1.02 | < 0.001 | < 0.001 | A, B |
| Triglycerides | 1.45 ± 1.03 | 1.66 ± 1.05 | 1.62 ± 1.03 | 1.57 ± 1.03 | < 0.001 | < 0.001 | A, B |
P-value1 indicates differences between plaque groups using F test; P-value.2 indicates differences between males and females using F test; the p-values shown in the “total” group represent the significance of plaque-gender interaction terms; pairwise difference indicates significant differences using Bonferroni adjustment method for multiple comparisons between (A) no plaque versus soft plaque, (B) no plaque versus calcified plaque, and (C) soft plaque versus calcified plaque. LDL, low-density lipoprotein; HDL, high-density lipoprotein
*Adjusted for age, body mass index, fasting blood glucose, hemoglobin A1c, systolic blood pressure, serum creatinine, and history of cardiovascular risk factors including hypertension, diabetes, smoking, and family history of premature coronary artery disease
Fig. 2Frequency of coronary plaque by gender
Demographic and clinical characteristics of the patients by coronary plaque groups
| No plaque | Soft plaque | Calcified plaque | Total | Test | ||
|---|---|---|---|---|---|---|
| Mean ± SD | 46.7 ± 10.5 | 50.4 ± 10.4 | 58.1 ± 9.9 | 50.3 ± 11.5 | < 0.001 | ANOVA |
| < 45 | 627 (40.8%) | 49 (26.2%) | 57 (8.2%) | 733 (30.3%) | < 0.001 | Chi |
| 45–64 | 847 (55.2%) | 121 (64.7%) | 457 (65.4%) | 1425 (58.9%) | ||
| ≥ 65 | 61 (4.0%) | 17 (9.1%) | 185 (26.5%) | 263 (10.9%) | ||
| Male | 879 (57.3%) | 124 (66.3%) | 495 (70.8%) | 1498 (61.9%) | < 0.001 | Chi |
| Female | 656 (42.7%) | 63 (33.7%) | 204 (29.2%) | 923 (38.1%) | ||
| Mean ± SD | 30.1 ± 5.7 | 30.8 ± 5.8 | 30.1 ± 5.3 | 30.2 ± 5.6 | 0.254 | ANOVA |
| Normal | 281 (19.0%) | 17 (9.2%) | 107 (15.5%) | 405 (17.2%) | 0.006 | Chi |
| Overweight | 522 (35.2%) | 75 (40.8%) | 272 (39.4%) | 869 (36.9%) | ||
| Obese | 679 (45.8%) | 92 (50.0%) | 312 (45.2%) | 1083 (45.9%) | ||
| Systolic | 127.1 ± 17.6 | 133.6 ± 19.2 | 132.6 ± 25.0 | 129.2 ± 20.3 | < 0.001 | ANOVA |
| Diastolic | 72.5 ± 12.0 | 72.8 ± 11.2 | 73.5 ± 12.7 | 72.8 ± 12.2 | 0.209 | ANOVA |
| Fasting glucose (mmol/L) | 6.05 ± 2.42 | 7.75 ± 3.65 | 6.67 ± 3.67 | 6.36 ± 2.98 | < 0.001 | KW |
| Hemoglobin A1c | 6.4 ± 1.5 | 7.3 ± 2.1 | 6.7 ± 1.8 | 6.5 ± 1.7 | < 0.001 | KW |
| Creatinine (mmol/L) | 73.8 ± 35.2 | 81.6 ± 96.1 | 78.0 ± 55.9 | 75.6 ± 49.0 | 0.003 | KW |
| Normal (> 90) | 970 (63.6%) | 117 (62.9%) | 378 (54.2%) | 1465 (60.8%) | < 0.001 | Chi |
| Mild (60–89) | 523 (34.3%) | 64 (34.4%) | 279 (40.0%) | 866 (35.9%) | ||
| Moderate (30–59) | 27 (1.8%) | 3 (1.6%) | 33 (4.7%) | 63 (2.6%) | ||
| Severe (15–29) | 1 (0.1%) | 0 (0.0%) | 5 (0.7%) | 6 (0.2%) | ||
| ESRD (< 15) | 4 (0.3%) | 2 (1.1%) | 3 (0.4%) | 9 (0.4%) | ||
| Diabetes | 334 (21.8%) | 85 (45.5%) | 274 (39.2%) | 693 (28.6%) | < 0.001 | Chi |
| Hypertension | 495 (32.3%) | 90 (48.1%) | 363 (51.9%) | 948 (39.2%) | < 0.001 | Chi |
| Hyperlipidemia | 193 (12.6%) | 53 (28.3%) | 166 (23.9%) | 412 (17.1%) | < 0.001 | Chi |
| Current smoking | 158 (10.3%) | 43 (23.0%) | 97 (13.9%) | 298 (12.3%) | < 0.001 | Chi |
| Family history of premature CAD | 116 (7.6%) | 14 (7.5%) | 66 (9.4%) | 196 (8.1%) | 0.309 | Chi |
| Mild risk (< 1%) | 447 (32.3%) | 26 (14.7%) | 38 (5.7%) | 511 (23.0%) | < 0.001 | Chi |
| Moderate (1 to < 5%) | 853 (61.6%) | 123 (69.5%) | 422 (63.6%) | 1398 (62.8%) | ||
| High risk (5 to < 10%) | 75 (5.4%) | 22 (12.4%) | 159 (23.9%) | 256 (11.5%) | ||
| Very high risk (≥ 10%) | 10 (0.7%) | 6 (3.4%) | 45 (6.8%) | 61 (2.7%) | ||
| Mild risk (< 1%) | 358 (25.6%) | 15 (8.3%) | 24 (3.5%) | 397 (17.6%) | < 0.001 | Chi |
| Moderate (1 to < 5%) | 604 (43.1%) | 62 (34.3%) | 234 (34.5%) | 900 (39.8%) | ||
| High risk (5 to < 10%) | 391 (27.9%) | 82 (45.3%) | 333 (49.1%) | 806 (35.7%) | ||
| Very high risk (≥ 10%) | 48 (3.4%) | 22 (12.2%) | 87 (12.8%) | 157 (6.9%) | ||
ESRD, end stage renal disease; CAD, coronary artery disease; SCORE, Systematic Coronary Risk Estimation of ESC/EAS; FRS, Framingham Risk Score; ANOVA, analysis of variance test; Chi. Chi-square test; KW, Kruskal–Wallis test
*Using glomerular filtration rate in mL/min
Crude means and standard deviations of blood lipids (mmol/L) by coronary plaque and gender groups
| No plaque | Soft plaque | Calcified plaque | Total | Pairwise difference | |||
|---|---|---|---|---|---|---|---|
| Total cholesterol | 4.81 ± 1.06 | 4.76 ± 1.27 | 4.58 ± 1.23 | 4.73 ± 1.14 | < 0.001 | 0.328 | B |
| LDL cholesterol | 3.01 ± 0.89 | 2.86 ± 1.04 | 2.77 ± 1.04 | 2.92 ± 0.96 | < 0.001 | 0.151 | B |
| HDL cholesterol | 1.15 ± 0.31 | 1.01 ± 0.28 | 1.10 ± 0.30 | 1.12 ± 0.30 | < 0.001 | < 0.001 | A, B, C |
| Triglycerides | 1.65 ± 1.03 | 2.12 ± 1.86 | 1.73 ± 1.11 | 1.72 ± 1.16 | 0.006 | < 0.001 | A, C |
| Total cholesterol | 4.81 ± 1.13 | 4.75 ± 1.28 | 4.75 ± 1.08 | 4.79 ± 1.13 | 0.610 | 0.328 | |
| LDL cholesterol | 2.90 ± 0.96 | 2.83 ± 0.97 | 2.76 ± 0.90 | 2.86 ± 0.95 | 0.110 | 0.151 | |
| HDL cholesterol | 1.33 ± 0.40 | 1.23 ± 0.41 | 1.33 ± 0.40 | 1.32 ± 0.40 | 0.036 | < 0.001 | A |
| Triglycerides | 1.46 ± 0.87 | 1.73 ± 1.57 | 1.65 ± 1.01 | 1.52 ± 0.97 | 0.012 | < 0.001 | B |
| Total cholesterol | 4.81 ± 1.09 | 4.76 ± 1.27 | 4.63 ± 1.19 | 4.75 ± 1.14 | < 0.001 | B | |
| LDL cholesterol | 2.96 ± 0.92 | 2.85 ± 1.01 | 2.76 ± 1.00 | 2.90 ± 0.96 | < 0.001 | B | |
| HDL cholesterol | 1.22 ± 0.36 | 1.09 ± 0.34 | 1.17 ± 0.35 | 1.20 ± 0.36 | < 0.001 | A, B, C | |
| Triglycerides | 1.57 ± 0.97 | 1.99 ± 1.77 | 1.70 ± 1.08 | 1.64 ± 1.09 | < 0.001 | A, B, C | |
P-value1 indicates differences between plaque groups using Kruskal–Wallis test; P-value2 indicates differences between males and females using Mann–Whitney test; pairwise difference indicates significant differences using Bonferroni adjustment method for multiple comparisons between (A) no plaque versus soft plaque, (B) no plaque versus calcified plaque, and (C) soft plaque versus calcified plaque. LDL, low-density lipoprotein; HDL, high-density lipoprotein
Control of blood lipids by coronary plaque and gender groups
| No plaque | Soft plaque | Calcified plaque | Total | Pairwise difference | |||
|---|---|---|---|---|---|---|---|
| Total cholesterol | 561 (64.0%) | 78 (62.9%) | 353 (71.3%) | 992 (66.3%) | 0.015 | 0.453 | B |
| LDL cholesterol | 216 (27.9%) | 30 (25.0%) | 126 (26.3%) | 372 (27.1%) | 0.721 | 0.005 | |
| HDL cholesterol | 602 (70.7%) | 65 (52.4%) | 297 (60.1%) | 964 (65.6%) | < 0.001 | < 0.001 | A, B |
| Triglycerides | 570 (65.0%) | 69 (55.6%) | 315 (63.9%) | 954 (63.9%) | 0.128 | < 0.001 | |
| Total cholesterol | 440 (67.2%) | 46 (73.0%) | 139 (68.1%) | 625 (67.8%) | 0.634 | 0.453 | |
| LDL cholesterol | 219 (35.0%) | 18 (29.5%) | 52 (26.1%) | 289 (32.6%) | 0.059 | 0.005 | |
| HDL cholesterol | 321 (50.6%) | 24 (38.1%) | 98 (48.0%) | 443 (49.1%) | 0.159 | < 0.001 | |
| Triglycerides | 482 (73.7%) | 42 (66.7%) | 138 (67.6%) | 662 (71.9%) | 0.155 | < 0.001 | |
| Total cholesterol | 1001 (65.3%) | 124 (66.3%) | 492 (70.4%) | 1617 (66.9%) | 0.062 | ||
| LDL cholesterol | 435 (31.0%) | 48 (26.5%) | 178 (26.3%) | 661 (29.2%) | 0.055 | ||
| HDL cholesterol | 923 (62.1%) | 89 (47.6%) | 395 (56.6%) | 1407 (59.3%) | < 0.001 | A, B | |
| Triglycerides | 1052 (68.7%) | 111 (59.4%) | 453 (65.0%) | 1616 (66.9%) | 0.016 | A | |
P-value1 indicates differences between plaque groups using chi-square; P-value2 indicates differences between males and females using chi-square; pairwise difference indicates significant differences using chi-square for multiple comparisons between (A) no plaque versus soft plaque, (B) no plaque versus calcified plaque, and (C) soft plaque versus calcified plaque. LDL, low-density lipoprotein; HDL, high-density lipoprotein